Cancer Treatment-Related Cardiotoxicity
Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prevent recurrence, prolong life and provide cure. However, many of these treatments can cause devastating cardiovascular complications for the patient such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. Developing and understanding optimal prevention, early detection and treatment strategies for cardiotoxicity related to anticancer treatment is a critical aspect of cancer patient care, and may have a significant impact on the overall prognosis and survival of cancer patients. These important clinical events are a significant challenge for both cardiologists and oncologists and will continue to be in the future, particularly due to an increasing aging population of patients with cancer and the introduction of many new targeted cancer therapies.
Efforts to identify individual toxicity risks and prevention strategies support the National Cancer Insitute's (NCI) goal of reducing the burden of cancer diagnoses and treatment outcomes. NCI's vision for the future includes precision medicine that not only provides effective therapy for eradicating disease, but also maintains the function of normal tissues, thus decreasing the burden of cancer throughout the survivorship spectrum.
NCI-sponsored Funding Opportunity Announcements (FOAs) related to cancer treatment-related cardiotoxicity research include:
- Improving Outcomes in Cancer Treatment-Related Cardiotoxicity - expires January 8, 2022
EGRP joins with other NCI Divisions, Offices, and Centers and other Institutes and Centers at the National Institutes of Health (NIH) to fund grant applications submitted in response to FOAs. View the full list of EGRP FOAs.
Workshops, Conferences, and Webinars
- Previous Events (sponsored by EGRP)
- Previous Events (not sponsored by EGRP)
- International CardiOncology Society (ICOS) (annual meetings)
- First International Conference on Cancer and the Heart (November 2010)
- Conference publications, Texas Heart Institute Journal 2011; 38(3): 246-269
- Toxicities and Symptoms of Cancer Therapy (April 2012)
- The Complex Patient: Biobehavioral Perspectives of Cancer and Cardiovascular Diseases and Comorbid Conditions (June 2011)
For general questions about cancer treatment-related cardiotoxicity, contact:
- Nonniekaye F. Shelburne, C.R.N.P., M.S., A.O.C.N. Program Director, Clinical and Translational Epidemiology Branch